How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
GMP Plasmid DNA Manufacturing Market
- By Plasmid DNA Type: Supercoiled Plasmid DNA, Open Circular Plasmid DNA, Linear Plasmid DNA
- By Application: Gene Therapy, DNA Vaccines, Cell Therapy, Research and Development, Synthetic Biology
- By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations (CMOs), Academic and Research Institutes
- By Production Scale: Laboratory Scale, Pilot Scale, Commercial Scale
- By Manufacturing Process: Fermentation-based Production, Cell Culture-based Production, Enzymatic Synthesis
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Supercoiled Plasmid DNA leads By Plasmid DNA Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the GMP Plasmid DNA Manufacturing Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Plasmid DNA Type 3
Application 5
End-User 4
Production Scale 3
Manufacturing Process 3
Companies profiled
Cobra Biologics (a Brammer Bio company)
VGXI Inc.
PlasmidFactory GmbH & Co. KG
Aldevron (a Danaher company)
Lonza Group AG
Thermo Fisher Scientific
Wuxi AppTec
Biovectra Inc.
Cytiva (formerly GE Healthcare Life Sciences)
Sartorius AG
Fujifilm Diosynth Biotechnologies
Minaris Regenerative Medicine GmbH
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Cobra Biologics (a Brammer Bio company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →VGXI Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →PlasmidFactory GmbH & Co. KG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Aldevron (a Danaher company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Wuxi AppTec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Biovectra Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cytiva (formerly GE Healthcare Life Sciences)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sartorius AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fujifilm Diosynth Biotechnologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Minaris Regenerative Medicine GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bioneer Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GenScript Biotech Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cell and Gene Therapy Catapult
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,151M by 2033 · 10.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Supercoiled Plasmid DNA73.9
- Open Circular Plasmid DNA18.4
- Linear Plasmid DNA7.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,636M → $3,374M · 9.5%
Europe$1,140M → $2,550M · 10.6%
Asia Pacific$1,041M → $2,242M · 10.1%
Latin America$644.4M → $1,469M · 10.9%
Middle East and Africa$495.7M → $1,181M · 11.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.612026
10.632027
10.642028
10.652029
10.672030
10.682031
10.692032
10.702033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Cobra Biologics (a Brammer Bio company)15.0
- VGXI Inc.20.1
- PlasmidFactory GmbH & Co. KG10.9
- Aldevron (a Danaher company)9.3
- Lonza Group AG6.8
- Thermo Fisher Scientific9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Plasmid DNA Type21.4%
Application17.3%
End-User16.6%
Production Scale19.4%
Manufacturing Process25.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.2
- Europe23.6
- Asia Pacific20.7
- Latin America13.6
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Cobra Biologics (a Brammer Bio company) | 96 | 79 | 89 | 96 | 74 | 88 | 87 |
| VGXI Inc. | 90 | 69 | 90 | 70 | 70 | 90 | 80 |
| PlasmidFactory GmbH & Co. KG | 84 | 83 | 67 | 73 | 85 | 73 | 78 |
| Aldevron (a Danaher company) | 72 | 63 | 64 | 65 | 80 | 75 | 70 |
| Lonza Group AG | 75 | 73 | 74 | 54 | 54 | 73 | 67 |
| Thermo Fisher Scientific | 61 | 50 | 61 | 63 | 62 | 71 | 61 |
| Wuxi AppTec | 63 | 64 | 44 | 48 | 54 | 50 | 54 |
| Biovectra Inc. | 51 | 45 | 52 | 42 | 56 | 54 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Cobra Biologics (a Brammer Bio company)
- VGXI Inc.
- PlasmidFactory GmbH & Co. KG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Cobra Biologics (a Brammer Bio company) | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| VGXI Inc. | ◐ | − | ✓ | ◐ | ✓ | ✓ |
| PlasmidFactory GmbH & Co. KG | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Aldevron (a Danaher company) | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Lonza Group AG | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| Wuxi AppTec | − | ◐ | − | − | ◐ | − |
| Biovectra Inc. | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Cobra Biologics (a Brammer Bio company)87
2VGXI Inc.80
3PlasmidFactory GmbH & Co. KG78
4Aldevron (a Danaher company)70
5Lonza Group AG67
6Thermo Fisher Scientific61
7Wuxi AppTec54
8Biovectra Inc.50
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Cobra Biologics (a Brammer Bio company)VGXI Inc.PlasmidFactory GmbH & Co. KG
Challenger2
Strong scale, closing on the leaders.
Aldevron (a Danaher company)Lonza Group AG
Contender1
Focused players with pockets of strength.
Thermo Fisher Scientific
Niche2
Specialists in a single segment or region.
Wuxi AppTecBiovectra Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Plasmid DNA Type in North America, then scale across GMP Plasmid DNA Manufacturing Market — a $375M beachhead inside a $5.98B market.
Beachhead (SOM)$375Mobtainable near-term
Serviceable (SAM)$2.13Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Supercoiled Plasmid DNA
Best fit — highest urgency & budget in Plasmid DNA Type.
Economic buyer77 fit
Open Circular Plasmid DNA
Strong fit — clear ROI and a fast path to value.
End user70 fit
Linear Plasmid DNA
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Plasmid DNA Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Plasmid DNA Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win GMP Plasmid DNA Manufacturing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified20%
Evaluation13%
Closed-won6%
$21.6KCAC
$116KLTV
5.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
GMP Plasmid DNA Manufacturing Market is a durable-growth opportunity — $7.69B by 2033, compounding at 9.5%.
TAM · 2025$3.71Btoday
TAM · 2033$7.69Bforecast
CAGR9.5%2027–2033
Cumulative$49.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.69BTotal addressable market
SAM$3.16BServiceable available market
SOM$691MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Plasmid DNA Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Plasmid DNA Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.69BLarge & growingTAM by 2033 at 9.5% CAGR
$3.16BServiceable nowreachable with today’s model
$691MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.00BBear6.2% CAGR
$7.69BBase9.5% CAGR
$9.84BBull12.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
GMP Plasmid DNA Manufacturing Market — a $6.27B market by 2033. Plan: grow share from 9.3% to 14.7%.
Market size · 2033$6.27Btotal addressable
Market CAGR3.9%2027–2033
Target share14.7%from 9.3% today
Revenue ambition$921Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.3% | 14.7% | Behind |
| Revenue | $527M | $921M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.0% | 45.8% | On track |
| Customer retention | 86.1% | 94.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Plasmid DNA Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Plasmid DNA Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $115M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Plasmid DNA Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the GMP Plasmid DNA Manufacturing Market conversation — a $6.21B market you can size, segment and defend in minutes.
Market size · 2033$6.21Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers943+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Plasmid DNA Type
Goal Grow share in Plasmid DNA Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 4 mopayback period
$78K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Cobra Biologics (a Brammer Bio company)VGXI Inc.PlasmidFactory GmbH & Co. KGAldevron (a Danaher company)Lonza Group AGThermo Fisher ScientificWuxi AppTecBiovectra Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your GMP Plasmid DNA Manufacturing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
GMP Plasmid DNA Manufacturing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →GMP Regulation Testing Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportGMP Viral Vector Manufacturing Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportGNSS & GPS System Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportGNSS (Global Navigation Satellite System) Positioning Chips Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportGNSS and GPS Antennas Market
Market size, share, segmentation and regional forecast.
$723M market · 2025 base year
View reportGNSS Ceramic Antenna Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportGNSS Ceramic Patch Antenna Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportGNSS Correction Services Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportGNSS Intelligent Deformation Monitoring and Early Warning System Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportGNSS Navigation Signal Simulators Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportGNSS Receiver Chips and Modules for OEM Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportGNSS Receiver Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.